Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

Table 1 Therapies to treat IgE-mediated allergic diseases

	Therapy	Type	Mechanism	Phase	References
Serum IgEneutralizization	Immuno adsorption	Plasma-pheresis	Removal of Ig and immune complex from blood	Marketed	Schmidt [23]
	Omalizumab	Monoclonal antibody	Bind Cε3 domain in heavy chain Fc of free IgE	Marketed	Chang [32]
	CMAB007	Biosimilar of omalizumab	Bind Cε3 domain in heavy chain Fc of free IgE	Phase III Local license	Bo Zhou [37]
	Ligelizumab	Monoclonal antibody	Target Cε3 domain of IgE	Phase II NCT01703312	Gauvreau [38]
	MEDI4212	Monoclonal antibody	Bind Cε3/Cε4 domain of IgE	Phase I NCT01544348	Sheldon [41]
	Recombinant ScFv	Single-chain antibody	Identify IgE, IgE-bound cells, and IgE-secreting cells	Preclinical	Lupinek [43]
IgE-effector cells	Anti-FcεRI Fab-conjugated celastrol-loaded micelles	Polymer	Prevent IgE interaction with mast cells, and kill mast cells	Preclinical	Peng [48]
IgE-effector cells	CTLA4Fcε	Fusion protein	Bind IgE receptors, FcεRI and FcεRII/CD23	Preclinical	Perez-Witzke [51]
IgE + B cells	Quilizumab	Monoclonal antibody	Target CεmX of IgE⁺ B cells	Phase II NCT01582503	Harris [59]
	Bsc-IgE/CD3	Monoclonal antibody	Eliminate IgE⁺ target cells by redirected T cells	Preclinical	Talay [61]
	XmAb7195	Monoclonal antibody	Form complex with B cell IgE receptors and FcγRII β	Phase I NCT02148744	Chu [66]

ISSN: 2045-7022